This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination
with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who
have progressed following treatment with osimertinib
The combination of osimertinib with savolitinib in this study (the SAVANNAH study) will
explore if the combination will overcome MET-amplification as a mechanism of resistance. The
SAVANNAH study will investigate the efficacy of osimertinib in combination with savolitinib
in patients with EGFRm+ and MET-amplified/overexpressed, locally advanced or metastatic NSCLC
who have progressed following treatment with osimertinib.
Eligible patients will be those with histologically or cytologically confirmed diagnosis of
EGFRm NSCLC that is locally advanced or metastatic and is not amenable to further surgery or
radiotherapy with curative intent. The disease must have progressed following treatment with
osimertinib. Patients must have confirmation of MET-amplified/overexpressed tumour by central
FISH testing (requirements summarised in the main body of the protocol and fully explained in
the Central Laboratory Manual). In patients centrally confirmed as
MET-amplified/overexpressed, MET-amplification/overexpression is defined as increased MET
gene copy number (by FISH). Patients must not have received prior or current treatment with
savolitinib or another MET inhibitor.
All patients confirmed as eligible will begin treatment on Day 1 with
osimertinib+savolitinib. Treatment will continue od in 28 day cycles until either objective
disease progression, unacceptable toxicity occurs, consent is withdrawn or another
discontinuation criterion is met.
Vulvar Dysplasia and Carcinoma,
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.